Psilocybin Pharmacology: 5-HT2A Receptor Agonism, Cortical Desynchronization & Synaptogenesis
Executive Summary
Upon oral ingestion, psilocybin undergoes rapid alkaline phosphatase dephosphorylation in the liver and gut to yield psilocin (4-hydroxy-N,N-dimethyltryptamine). Psilocin selectively binds to neocortical 5-HT2A serotonin receptors, stimulating downstream phospholipase C (PLC) and BDNF-TrkB pathways to trigger immediate structural neuroplasticity and dendritic arborization.
1. Pharmacokinetics: The Dephosphorylation Cascade
Psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) functions primarily as a prodrug. The phosphate ester group confers exceptional chemical stability against ambient atmospheric oxidation, but renders the native molecule incapable of crossing the blood-brain barrier with high affinity.
Upon oral administration, endogenous brush-border alkaline phosphatases and hepatic esterases hydrolyze the phosphate ester moiety at physiological pH, liberating the lipophilic active metabolite psilocin (4-HO-DMT). Psilocin rapidly distributes across the blood-brain barrier via passive lipophilic diffusion, reaching peak plasma concentration (Tmax) within 50 to 90 minutes.
2. 5-HT2A Receptors and Neocortical Pyramidal Layer V
Psilocin functions as a partial agonist at 5-HT2A, 5-HT2C, and 5-HT1A receptor subtypes. However, its signature subjective and neuroplastic actions are mediated almost exclusively by high-density 5-HT2A receptors localized along the apical dendrites of layer V pyramidal neurons in the prefrontal and retrosplenial cortex.
Unlike endogenous serotonin (5-HT), which induces balanced intracellular signaling, psilocin acts as a functionally selective (biased) agonist, robustly recruiting Gq-mediated phospholipase C (PLC) and non-canonical beta-arrestin scaffolding complexes.
3. Dendritic Spine Density & TrkB-BDNF Synthesis
Recent two-photon in vivo imaging studies confirm that 5-HT2A agonism rapidly triggers the expression of immediate early genes (Egr1, Egr2, c-Fos) and doubles the synthesis of Brain-Derived Neurotrophic Factor (BDNF).
This trophic surge activates Tropomyosin receptor kinase B (TrkB) and mammalian target of rapamycin (mTOR) complexes, driving actin polymerization and the physical formation of new mushroom-shaped dendritic spines within the prefrontal cortex.
Primary Scientific Citations
- Ly, C., Greb, A. C., Cameron, L. P., et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports • DOI: 10.1016/j.celrep.2018.05.022
- Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience • DOI: 10.1038/s41583-020-0367-8